Literature DB >> 20653840

Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).

A J Rose1, E M Hylek, A Ozonoff, A S Ash, J I Reisman, D R Berlowitz.   

Abstract

BACKGROUND: In patients receiving oral anticoagulation, improved control can reduce adverse outcomes such as stroke and major hemorrhage. However, little is known about patient-level predictors of anticoagulation control.
OBJECTIVES: To identify patient-level predictors of oral anticoagulation control in the outpatient setting. PATIENTS/
METHODS: We studied 124,619 patients who received oral anticoagulation from the Veterans Health Administration from October 2006 to September 2008. The outcome was anticoagulation control, summarized using percentage of time in therapeutic International Normalized Ratio range (TTR). Data were divided into inception (first 6 months of therapy; 39,447 patients) and experienced (any time thereafter; 104,505 patients). Patient-level predictors of TTR were examined by multivariable regression.
RESULTS: Mean TTRs were 48% for inception management and 61% for experienced management. During inception, important predictors of TTR included hospitalizations (the expected TTR was 7.3% lower for those with two or more hospitalizations than for the non-hospitalized), receipt of more medications (16 or more medications predicted a 4.3% lower than for patients with 0-7 medications), alcohol abuse (-4.6%), cancer (-3.1%), and bipolar disorder (-2.9%). During the experienced period, important predictors of TTR included hospitalizations (four or more hospitalizations predicted 9.4% lower TTR), more medications (16 or more medications predicted 5.1% lower TTR), alcohol abuse (-5.4%), female sex (- 2.9%), cancer (-2.7%), dementia (-2.6%), non-alcohol substance abuse (-2.4%), and chronic liver disease (-2.3%).
CONCLUSIONS: Some patients receiving oral anticoagulation therapy are more challenging to maintain within the therapeutic range than others. Our findings can be used to identify patients who require closer attention or innovative management strategies to maximize benefit and minimize harm from oral anticoagulation therapy.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653840     DOI: 10.1111/j.1538-7836.2010.03996.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  55 in total

Review 1.  Promise of factor Xa inhibition in atrial fibrillation.

Authors:  Sana M Al-Khatib; John H Alexander; Renato D Lopes; Kenneth W Mahaffey; Manesh R Patel; Christopher B Granger
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

2.  Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration.

Authors:  Adam J Rose; Beth Ann Petrakis; Patricia Callahan; Scott Mambourg; Dimple Patel; Elaine M Hylek; Barbara G Bokhour
Journal:  Health Serv Res       Date:  2012-02-02       Impact factor: 3.402

3.  The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy.

Authors:  Hanan S Khreizat; Peter Whittaker; Kristy D Curtis; Gerald Turlo; Candice L Garwood
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

4.  SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience.

Authors:  Akash Kataruka; Xiaowen Kong; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Gregory D Krol; Scott Kaatz; Michael W McNamara; James B Froehlich; Geoffrey D Barnes
Journal:  Vasc Med       Date:  2017-02-01       Impact factor: 3.239

Review 5.  Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project.

Authors:  Graziano Onder; Francesco Landi; Domenico Fusco; Andrea Corsonello; Matteo Tosato; Miriam Battaglia; Simona Mastropaolo; Silvana Settanni; Manuela Antocicco; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

6.  Capsule commentary on Paradise et al., Outcomes of anticoagulation therapy in patients with mental health conditions.

Authors:  Ankur Gupta
Journal:  J Gen Intern Med       Date:  2014-06       Impact factor: 5.128

7.  Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods.

Authors:  Julia C Lea; Catherine K Floroff; Amanda I Ingemi; Gary R Zeevi
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 8.  Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.

Authors:  Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 9.  Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?

Authors:  Jenny I Shen; Mintu P Turakhia; Wolfgang C Winkelmayer
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-11       Impact factor: 2.894

10.  Outcomes of anticoagulation therapy in patients with mental health conditions.

Authors:  Helen T Paradise; Dan R Berlowitz; Al Ozonoff; Donald R Miller; Elaine M Hylek; Arlene S Ash; Guneet K Jasuja; Shibei Zhao; Joel I Reisman; Adam J Rose
Journal:  J Gen Intern Med       Date:  2014-02-19       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.